IV Haloperidol for the Treatment of Headache in the ED
Primary Purpose
Headache, Migraine Disorders
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Haloperidol
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Headache
Eligibility Criteria
Inclusion Criteria:
- Emergency Department patients that complain of headache or migraine
- Males and females age 13-55
- English is primary language
Exclusion Criteria:
- Abnormal blood pressure (>200/100)
- Sudden rapid onsent (normal to worst pain in minutes)
- Fever
- Trauma
- Any history of masses, strokes, head injury or other causes of abnormal anatomy
- QT greater than 450 ms on EKG
- Allergy to Haldon
- Any altered mental status (GCS <15)
- Pregnancy
- Any abnormalities on neurologic exam
- Any clinician concern that would require CT scan of brain
- Any prisoner or ward of state
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Haloperidol
Placebo
Arm Description
Outcomes
Primary Outcome Measures
>50% reduction in pain per Visual Analog Scale (VAS)
Secondary Outcome Measures
Full Information
NCT ID
NCT02747511
First Posted
April 19, 2016
Last Updated
December 8, 2017
Sponsor
Western Michigan University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02747511
Brief Title
IV Haloperidol for the Treatment of Headache in the ED
Official Title
Intravenous Haloperidol for the Treatment of Headache in the Emergency Department
Study Type
Interventional
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
October 2015 (undefined)
Primary Completion Date
October 2017 (Actual)
Study Completion Date
October 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Western Michigan University School of Medicine
4. Oversight
5. Study Description
Brief Summary
Single center, double-blind, randomized, placebo-controlled trial evaluating analog pain scores in patients who present to the emergency department (ED) with a complaint of headache. A total of 150 patients age 13-55 presenting to the emergency department with headache will be enrolled from October 2015 - October 2016. Patients will be randomized and pain scores and side effects will be recorded at 0, 30, 60, and 90 minutes. Follow-up will be performed by telephone at 24 hours.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Headache, Migraine Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
118 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Haloperidol
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Haloperidol
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
0.9% Sodium Chloride
Primary Outcome Measure Information:
Title
>50% reduction in pain per Visual Analog Scale (VAS)
Time Frame
90 minute interval
10. Eligibility
Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Emergency Department patients that complain of headache or migraine
Males and females age 13-55
English is primary language
Exclusion Criteria:
Abnormal blood pressure (>200/100)
Sudden rapid onsent (normal to worst pain in minutes)
Fever
Trauma
Any history of masses, strokes, head injury or other causes of abnormal anatomy
QT greater than 450 ms on EKG
Allergy to Haldon
Any altered mental status (GCS <15)
Pregnancy
Any abnormalities on neurologic exam
Any clinician concern that would require CT scan of brain
Any prisoner or ward of state
12. IPD Sharing Statement
Citations:
PubMed Identifier
32402480
Citation
McCoy JJ, Aldy K, Arnall E, Petersen J. Treatment of Headache in the Emergency Department: Haloperidol in the Acute Setting (THE-HA Study): A Randomized Clinical Trial. J Emerg Med. 2020 Jul;59(1):12-20. doi: 10.1016/j.jemermed.2020.04.018. Epub 2020 May 10.
Results Reference
derived
Learn more about this trial
IV Haloperidol for the Treatment of Headache in the ED
We'll reach out to this number within 24 hrs